Investor Presentation

We are the innovation leader in bioprocessing Enabling efficient, single-use, high-productivity biological drug manufacturing $802M 2022 Revenue +20% +22% organic Differentiated technologies R REPLIGEN +42% 5-year CAGR +26% 5-year avg. base growth Revenue growth through acquisitions, innovation 8 M&A Deals since YE 2016 Diversified customer base, all biological drug modalities 10 Disruptive technology launches 7% of revenue in 2022 was from products launched 2021-2022 65% Clinical 35% Commercial (excl. COVID) 18 global facilities, 2,000+ employees 2022 figures reflects full-year results as of our Q4 earnings call Feb. 22, 2023. "Base" excludes COVID-related & inorganic M&A revenue. 4

View entire presentation